Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Food Scene
Community Directory
Community Service
Restaurant Guide
Rescue Me
Other
Specials
Entertainment Now
Spring Wellness
Home & Garden
Home Improvement
Home & Realty
Horizons
Outdoor Guide
Progress
Women
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2022 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acadia Pharmaceutica
(NQ:
ACAD
)
20.00
+0.09 (+0.45%)
Streaming Delayed Price
Updated: 2:00 PM EST, Feb 3, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
552,323
Open
19.54
Bid (Size)
20.00 (4)
Ask (Size)
20.02 (5)
Prev. Close
19.91
Today's Range
19.53 - 20.11
52wk Range
12.24 - 28.05
Shares Outstanding
161,930,994
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Analyst Expectations for ACADIA Pharmaceuticals's Future
January 31, 2023
Via
Benzinga
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
January 09, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Performance
YTD
+22.55%
+22.55%
1 Month
+22.55%
+22.55%
3 Month
+34.95%
+34.95%
6 Month
+28.04%
+28.04%
1 Year
-14.57%
-14.57%
More News
Read More
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
January 03, 2023
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
December 21, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Mizuho Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
December 21, 2022
Via
Benzinga
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
November 25, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Acadia Trofinetide Phase III Clinical Top-Line Results Positive
November 16, 2022
Via
AB Newswire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
November 08, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 02, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
November 04, 2022
Via
Benzinga
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
October 31, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Via
Benzinga
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
October 27, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
October 20, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
October 13, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
October 04, 2022
From
Acadia Pharmaceuticals
Via
Business Wire
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
September 12, 2022
Via
Benzinga
U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review
September 12, 2022
Via
Benzinga
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
September 12, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
September 01, 2022
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
Via
Benzinga
ACADIA Pharmaceuticals's Return On Capital Employed Insights
August 29, 2022
Via
Benzinga
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
August 09, 2022
Via
Benzinga
ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees
August 09, 2022
Via
Benzinga
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
August 09, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
